Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts [Seeking Alpha]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Seeking Alpha
Vafseo's commercial momentum is supported by broad U.S. dialysis access, protocol-driven adherence gains, and anticipated revenue normalization post temporary 4Q25 inventory reductions. AKBA's pipeline is set for key 2026 catalysts, including praliciguat Phase 2 FSGS data and AKB-097 Phase 2 initiation, diversifying beyond its anaemia franchise. Valuation remains modest at 1.8x EV/sales, with cash runway of 12–15 months and equity value highly sensitive to Vafseo execution and pipeline progress. zorazhuang/iStock via Getty Images Thesis: Vafseo post sell-off As you know, Akebia Therapeutics, Inc. ( AKBA ) makes money mainly via the commercialisation of Vafseo. It's an oral therapy approved for the treatment of anaemia due to chronic kidney disease (CKD) in adults receiving This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ne
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline OutlookGlobeNewswire
- Akebia announces first patient dosed in Phase 2 trial of praliciguat [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)GlobeNewswire
- Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
AKBA
Earnings
- 11/10/25 - In-Line
AKBA
Sec Filings
- 1/12/26 - Form 8-K
- 12/1/25 - Form 8-K
- 11/17/25 - Form 8-K
- AKBA's page on the SEC website